Development and validation of a law-cost cerebral oximeter for detection of cognitive impairment and Alzheimer's disease

用于检测认知障碍和阿尔茨海默病的低成本脑血氧计的开发和验证

基本信息

批准号：
10214169
负责人：
Maria Angela Franceschini
金额：
$ 46.2万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-05-01 至 2024-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10214169
关键词：
Acute Age Aging Alzheimer&apos s Disease Alzheimer&apos s disease diagnosis Alzheimer&apos s disease pathology Alzheimer&apos s disease risk Amyloid Area Behavioral Benign Blood Vessels Bluetooth Brain Cardiovascular system Cerebrovascular Circulation Cerebrovascular Disorders Cerebrovascular Physiology Cerebrovascular Trauma Cerebrum Clinical Clinical Research Cognitive Cognitive aging Communities Complement Computer software Dependence Detection Deterioration Development Devices Disease Elderly Etiology Evaluation Event Frequencies Future Goals Gold Health Heart Heart Rate Hemoglobin Heterogeneity Impaired cognition Impairment Individual Intervention Laws Lesion Link Magnetic Resonance Imaging Measurement Measures Methods Monitor Near-Infrared Spectroscopy Nerve Degeneration Neurobehavioral Manifestations Neurodegenerative Disorders Pathologic Pathology Patients Performance Pharmacology Physiological Physiology Predictive Factor Prevention Primary Health Care Production Property Research Risk Signal Transduction Stroke Technology Testing Therapeutic Time Tissues Translating Validation Vascular Dementia Vascular Diseases White Matter Hyperintensity Wireless Technology Work attenuation brain tissue cerebrovascular cerebrovascular health cerebrovascular pathology clinical Diagnosis clinical care clinical practice clinically significant cognitive capacity cost data streams design flexibility handheld mobile device high standard indexing interest lifestyle factors medical specialties medically underserved population mild cognitive impairment neurocognitive disorder neuroimaging neurovascular novel prevent prototype relating to nervous system screening sensor signal processing socioeconomics tau Proteins tissue injury tissue oxygenation vascular cognitive impairment and dementia web interface white matter

项目摘要

Project Summary/Abstract. It is now understood that cerebrovascular dysfunction contributes to a host of neurocognitive disorders including the reduction in cognitive capacity with typical aging as well as the more serious impairments resulting from vascular disease and dementia. Cerebrovascular pathology is also highly prevalent in patients with Alzheimer’s disease (AD) and is an important factor contributing to the conversion from an independent state of mild cognitive impairment to the functional dependence associated with Alzheimer’s dementia. Thus, vascular health and disease are important mechanisms contributing to heterogeneity in cognitive aging and progression to vascular and Alzheimer’s dementias. Unlike the proteinopathies of AD and other neurodegenerative conditions, vascular health is immediately modifiable through behavioral and lifestyle factors, as well as a range of pharmacological and device related interventions. Thus, it is critical to develop methods for quantitative tracking of metrics of cerebrovascular health that could be used to detect the earliest stages of abnormalities that may require intervention. Optimally, such technology would be wireless, mobile/web interfacing and would be very low cost allowing for accessibility to traditionally medically underserved populations. We have designed and prototyped such a device that would permit widespread cerebrovascular monitoring in older adults. The goal of this R21 proposal is to complete the development of, and to validate this novel low-cost cerebral oximeter that can be used to screen for cerebrovascular disorders that contribute to cognitive impairment and increase risk for the development of AD. To do so, we will aim to Specific Aim 1: 1a) complete the design and casing and programming of our existing developed device; 1b) to optimize the design for high performance and reliable physiological signal detection; Aim 2: 2a) to validate performance of the low-cost mobile oximeter relative to gold standard high grade cerebral oximeter; 2b) to validate performance of the low-cost mobile oximeter relative to cerebral physiology measurements obtained by magnetic resonance imaging. The proposed sensor would promote widespread cerebrovascular monitoring in individuals at risk for vascular dysfunction and neurocognitive disorders. Ultimately, in the future, we aim for this sensor to be translated for use in clinical practice for generalized primary care as well as specialty clinical use.

项目摘要/摘要。现在了解到脑血管功能障碍会导致许多神经认知疾病包括典型衰老以及更严重的障碍的认知能力的降低由血管疾病和痴呆症引起。脑血管病理在患者中也很普遍患有阿尔茨海默氏病（AD），是导致独立转换的重要因素与阿尔茨海默氏痴呆症相关的功能依赖性的轻度认知障碍状态。那，血管健康和疾病是重要机制，导致认知衰老和发展为血管和阿尔茨海默氏症的痴呆症。与AD和其他的蛋白质病不同神经退行性条件，通过行为和生活方式可以立即修改血管健康因素以及一系列相关的药物和设备干预措施。那是至关重要的可用于检测最早的脑血管健康指标定量跟踪的方法可能需要干预的异常阶段。最佳地，这样的技术将是无线的，移动/网络接口将是非常低的成本，允许传统上可访问性服务不足的人群。我们设计并原型制作了这样的设备，该设备将允许宽度老年人的脑血管监测。该R21提案的目的是完成，并验证可用于筛查脑血管疾病的新型低成本脑充氧剂这有助于认知障碍并增加AD发展的风险。为此，我们的目标是特定目的1：1a）完成我们现有开发设备的设计，外壳和编程； 1b）至优化设计高性能和可靠的物理信号检测；目标2：2a）验证低成本移动氧合相对于金标准高级脑充氧的性能； 2b）至相对于获得的脑生理测量，验证低成本移动氧合剂的性能通过磁共振成像。提出的传感器将促进宽度脑血管监测在有血管功能障碍和神经认知障碍风险的个体中。最终，将来我们的目标是该传感器要翻译用于临床实践，用于广义初级保健以及专业临床使用。